HIV-1 tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes

Journal of Neuroimmune Pharmacology

Volumn 7, Issue 3, 2012, Pages 629-639

  Midde, Narasimha M ^a   Gomez, Adrian M ^a   Zhu, Jun ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dopamine transporter; HIV 1 Tat; Protein kinase C; Trafficking; Uptake; Vesicular monoamine transporter

Indexed keywords

BISINDOLYLMALEIMIDE; DOPAMINE TRANSPORTER; TRANSACTIVATOR PROTEIN; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CELL SURFACE; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREACTIVITY; MALE; MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; HIV-1; MALE; MEMBRANE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOSOMES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84866095641     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-012-9369-9     Document Type: Article

References (74)

1. Boudanova E, Navaroli DM,Melikian HE (2008) Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent. Neuropharmacology 54:605-612
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
3. Buch S, Yao H, Guo M, Mori T, Su TP, Wang J (2011) Cocaine and HIV-1 interplay: Molecular mechanisms of action and addiction. J Neuroimmune Pharmacol 6:503-515
4. Campbell GR, Loret EP (2009) What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology 6:50
5. Cass WA, Harned ME, Peters LE, Nath A, Maragos WF (2003) HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 984:133-142 (Pubitemid 36976802)
6. Cervinski MA, Foster JD, Vaughan RA (2005) Psychoactive substrates stimulate dopamine transporter phosphorylation and downregulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J Biol Chem 280:40442-40449 (Pubitemid 41780531)
7. Chang L,Wang GJ, Volkow ND, Ernst T, Telang F, Logan J, Fowler JS (2008) Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. NeuroImage 42:869-878
8. Chen R, Furman CA, Gnegy ME (2010) Dopamine transporter trafficking: Rapid response on demand. Futur Neurol 5:123
9. Chi L, Reith ME (2003) Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J Pharmacol Exp Ther 307:729-736 (Pubitemid 37310690)
10. Chudasama Y, Robbins TW (2006) Functions of frontostriatal systems in cognition: Comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol Psychol 73:19-38 (Pubitemid 43732470)
11. Daniels GM, Amara SG (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J Biol Chem 274:35794-35801 (Pubitemid 129512883)
12. Del Valle L, Croul S, Morgello S, Amini S, Rappaport J, Khalili K (2000) Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J Neurovirol 6:221-228 (Pubitemid 30447166)
13. Egana LA, Cuevas RA, Baust TB, Parra LA, Leak RK, Hochendoner S, Pena K, Quiroz M, Hong WC, Dorostkar MM, Janz R, Sitte HH, Torres GE (2009) Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3. J Neurosci 29:4592-4604
14. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A 93:5166-5171 (Pubitemid 26162890)
15. Ernst T, Yakupov R, Nakama H, Crocket G, Cole M, Watters M, Ricardo-Dukelow ML, Chang L (2009) Declined neural efficiency in cognitively stable human immunodeficiency virus patients. Ann Neurol 65:316-325
16. Ferris MJ, Mactutus CF, Booze RM (2008) Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: Current status of dopamine system vulnerability in Neuro-AIDS. Neurosci Biobehav Rev 32:883-909
17. Fiala M, Gan XH, Zhang L, House SD, Newton T, Graves MC, Shapshak P, Stins M, Kim KS, Witte M, Chang SL (1998) Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine's connection to AIDS dementia and vasculitis? Adv Exp Med Biol 437:199-205 (Pubitemid 28350097)
18. Fleckenstein A, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698
19. Fleckenstein AE, Volz TJ, Hanson GR (2009) Psychostimulantinduced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 56(Suppl 1):133-138
20. Furman CA, Chen R, Guptaroy B, Zhang M, Holz RW, Gnegy M (2009) Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: Live-cell imaging using total internal reflection fluorescence microscopy. J Neurosci 29:3328-3336
21. Gorentla BK, Vaughan RA (2005) Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation. Neuropharmacology 49:759-768 (Pubitemid 41483882)
22. Gu H,Wall SC, Rudnick G (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269:7124-7130 (Pubitemid 24217896)
23. Gulley JM, Doolen S, Zahniser NR (2002) Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J Neurochem 83:400-411 (Pubitemid 35191405)
24. Hu S, Sheng WS, Lokensgard JR, Peterson PK, Rock RB (2009) Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage. J Neurovirol 15:401-410
25. Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O, Male D, Everall I (2000) Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol 6:145-155 (Pubitemid 30303573)
26. Johnson RG Jr (1988) Accumulation of biological amines into chromaffin granules: A model for hormone and neurotransmitter transport. Physiol Rev 68:232-307 (Pubitemid 18035237)
27. Johnson LA, Furman CA, Zhang M, Guptaroy B, Gnegy ME (2005) Rapid delivery of the dopamine transporter to the plasmalemmal membrane upon amphetamine stimulation. Neuropharmacology 49:750-758 (Pubitemid 41483881)
28. Jones M, Olafson K, Del Bigio MR, Peeling J, Nath A (1998) Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement. J Neuropathol Exp Neurol 57:563-570
29. Kass MD, Liu X, Vigorito M, Chang L, Chang SL (2010) Methamphetamine- induced behavioral and physiological effects in adolescent and adult HIV-1 transgenic rats. J Neuroimmune Pharmacol 5:566-573
30. Kumar AM, Fernandez JB, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL, Kumar M (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15:257-274
31. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M (2011) Human immunodeficiency virus infection in the CNS and decreased dopamine availability: Relationship with neuropsychological performance. J Neurovirol 17:26-40
32. Lamers SL, Salemi M, Galligan DC, Morris A, Gray R, Fogel G, Zhao L, McGrath MS (2010) Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain. J Neurovirol 16:230-241
33. Larrat EP, Zierler S (1993) Entangled epidemics: Cocaine use and HIV disease. J Psychoactive Drugs 25:207-221 (Pubitemid 23298776)
34. Li W, Li G, Steiner J, Nath A (2009) Role of Tat protein in HIV neuropathogenesis. Neurotox Res 16:205-220
35. Lin Z, Itokawa M, Uhl GR (2000) Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression. FASEB J 14:715-728 (Pubitemid 30198570)
36. Ma M, Nath A (1997) Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol 71:2495-2499 (Pubitemid 27078635)
37. Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A (1995) Human immunodeficiency virus type 1 tat activates non-N-methyl-D-Aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 37:373-380
38. McArthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-Associated neurocognitive disorders: Mind the gap. Ann Neurol 67:699-714
39. McCune JM (2001) The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410:974-979 (Pubitemid 32335848)
40. Meade CS, Conn NA, Skalski LM, Safren SA (2011a) Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J Behav Med 34:128-138
41. Meade CS, Lowen SB, MacLean RR, Key MD, Lukas SE (2011b) fMRI brain activation during a delay discounting task in HIVpositive adults with and without cocaine dependence. Psychiatry Res 192:167-175
42. Melikian HE (2004) Neurotransmitter transporter trafficking: Endocytosis, recycling, and regulation. Pharmacol Ther 104:17-27 (Pubitemid 39410560)
43. Middleton LS, Apparsundaram S, King-Pospisil KA, Dwoskin LP (2007) Nicotine increases dopamine transporter function in rat striatum through a trafficking-independent mechanism. Eur J Pharmacol 554:128-136 (Pubitemid 44879410)
44. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and alphasynuclein causes selective death of substantia nigra neurons. Neuron 62:218-229
45. Nath A, Clements JE (2011) Eradication of HIV from the brain: Reasons for pause. AIDS 25:577-580
46. Nath A, Conant K, Chen P, Scott C, Major EO (1999) Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 274:17098-17102
47. New DR, Ma M, Epstein LG, Nath A, Gelbard HA (1997) Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. J Neurovirol 3:168-173 (Pubitemid 27182510)
48. Norman LR, Basso M, Kumar A, Malow R (2009) Neuropsychological consequences of HIV and substance abuse: A literature review and implications for treatment and future research. Curr Drug Abuse Rev 2:143-156
49. Perry SW, Barbieri J, Tong N, Polesskaya O, Pudasaini S, Stout A, Lu R, Kiebala M, Maggirwar SB, Gelbard HA (2010) Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax. J Neurosci 30:14153-14164
50. Richards TL, Zahniser NR (2009) Rapid substrate-induced downregulation in function and surface localization of dopamine transporters: Rat dorsal striatum versus nucleus accumbens. J Neurochem 108:1575-1584
51. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915-1921 (Pubitemid 47329768)
52. Rudnick G, Clark J (1993) From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144:249-263 (Pubitemid 23290252)
53. Sager JJ, Torres GE (2011) Proteins interacting with monoamine transporters: Current state and future challenges. Biochemistry 50:7295-7310
54. Sardar AM, Czudek C, Reynolds GP (1996) Dopamine deficits in the brain: The neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 7:910-912 (Pubitemid 26167975)
55. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A 97:6850-6855 (Pubitemid 30412803)
56. Scheller C, Arendt G, Nolting T, Antke C, Sopper S, Maschke M, Obermann M, Angerer A, Husstedt IW, Meisner F, Neuen-Jacob E, Muller HW, Carey P, Ter Meulen V, Riederer P, Koutsilieri E (2010) Increased dopaminergic neurotransmission in therapynaive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm 117:699-705
57. Shan J, Javitch JA, Shi L, Weinstein H (2011) The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter. PLoS One 6:e16350
58. Silvers JM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM (2007) Neurotoxicity of HIV-1 Tat protein: Involvement of D1 dopamine receptor. Neurotoxicology 28:1184-1190 (Pubitemid 350026595)
59. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102-4108
60. Theodore S, Cass WA, Maragos WF (2006) Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 137:925-935 (Pubitemid 43053955)
61. Thwar PK, Guptaroy B, Zhang M, Gnegy ME, Burns MA, Linderman JJ (2007) Simple transporter trafficking model for amphetamineinduced dopamine efflux. Synapse 61:500-514 (Pubitemid 46753969)
62. Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P (2007) Persistence of neuropsychologic deficits despite long-Term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: Prevalence and risk factors. J Acquir Immune Defic Syndr 45:174-182 (Pubitemid 46869810)
63. Vergo S, Johansen JL, Leist M, Lotharius J (2007) Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res 1185:18-32 (Pubitemid 350166316)
64. Volz TJ, Hanson GR, Fleckenstein AE (2007) The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem 101:883-888 (Pubitemid 46683868)
65. Wallace DR, Dodson S, Nath A, Booze RM (2006) Estrogen attenuates gp120-And tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59:51-60 (Pubitemid 41706154)
66. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, Fowler JS (2004) Decreased brain dopaminergic transporters in HIVassociated dementia patients. Brain 127:2452-2458 (Pubitemid 39472973)
67. Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS (1999) A prospective study of HIV disease progression in female and male drug users. AIDS 13:257-262 (Pubitemid 29050414)
68. Zahniser NR, Sorkin A (2004) Rapid regulation of the dopamine transporter: Role in stimulant addiction? Neuropharmacology 47:80-91 (Pubitemid 39298254)
69. Zhu J, Reith ME (2008) Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol Disord Drug Targets 7:393-409
70. Zhu J, Green T, Bardo MT, Dwoskin LP (2004) Environmental enrichment enhances sensitization to GBR 12935-induced activity and decreases dopamine transporter function in the medial prefrontal cortex. Behav Brain Res 148:107-117 (Pubitemid 37543660)
71. Zhu J, Apparsundaram S, Bardo MT, Dwoskin LP (2005) Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex. J Neurochem 93:1434-1443 (Pubitemid 40853266)
72. Zhu J, Apparsundaram S, Dwoskin LP (2009a) Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex. J Pharmacol Exp Ther 328:931-939
73. Zhu J, Mactutus CF,Wallace DR, Booze RM (2009b) HIV-1 Tat proteininduced rapid and reversible decrease in [3H]dopamine uptake: Dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 329:1071-1083
74. Zhu J, Ananthan S, Mactutus CF, Booze RM (2011) Recombinant HIV-1TAT(1-86) allosterically modulates dopamine transporter activity. Synapse.